title: Delivery of gene silencing agents for breast cancer therapy.
abstract: The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.
authors: Haifa
authors: H
authors: Shen
authors: Vivek
authors: V
authors: Mittal
authors: Mauro
authors: M
authors: Ferrari
authors: Jenny
authors: J
authors: Chang
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D020868:Gene Silencing; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D035683:MicroRNAs / Q000235:genetics; D034622:RNA Interference
chemical_list: D035683:MicroRNAs
references: Cancer Res. 2010 May 1;70(9):3687-96
references: 20430760
references: Nat Mater. 2012 Feb 26;11(4):316-22
references: 22367004
references: Proc Natl Acad Sci U S A. 2010 May 4;107(18):8231-6
references: 20406904
references: J Clin Invest. 2009 Mar;119(3):661-73
references: 19229107
references: PLoS One. 2012;7(6):e39520
references: 22761812
references: Cancer Cell. 2007 Oct;12(4):395-402
references: 17936563
references: Sci Transl Med. 2012 Apr 18;4(130):130ra48
references: 22517885
references: Cancer Biol Ther. 2009 Jun;8(11):1027-34
references: 19395869
references: Nanomedicine (Lond). 2012 Jan;7(1):65-78
references: 22191778
references: Cancer Res. 2007 Oct 15;67(20):9762-70
references: 17942906
references: Small. 2013 May 27;9(9-10):1799-808
references: 23293085
references: Clin Cancer Res. 2011 Apr 1;17(7):1713-21
references: 21300758
references: Mol Endocrinol. 2007 May;21(5):1132-47
references: 17312270
references: J Control Release. 2012 Feb 28;158(1):148-55
references: 22062689
references: Gene Ther. 2006 Aug;13(16):1222-34
references: 16625243
references: Nat Biotechnol. 2008 May;26(5):561-9
references: 18438401
references: J Natl Cancer Inst. 2008 May 7;100(9):672-9
references: 18445819
references: Cell. 2005 Mar 11;120(5):635-47
references: 15766527
references: J Natl Cancer Inst. 2010 May 19;102(10):706-21
references: 20388878
references: Nature. 2001 May 24;411(6836):494-8
references: 11373684
references: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references: 16172456
references: Science. 2008 Feb 1;319(5863):620-4
references: 18239126
references: Trends Biotechnol. 2010 Apr;28(4):181-8
references: 20079548
references: Clin Cancer Res. 2012 Nov 1;18(21 Suppl):S1-100
references: 22977188
references: Clin Cancer Res. 2013 Apr 1;19(7):1806-15
references: 23386691
references: Nanomedicine (Lond). 2012 Apr;7(4):493-506
references: 21995500
references: PLoS One. 2012;7(8):e30207
references: 22879872
references: Bioconjug Chem. 2003 Nov-Dec;14(6):1122-32
references: 14624625
references: J Clin Invest. 2009 Aug;119(8):2231-44
references: 19620771
references: J Clin Oncol. 2001 Mar 1;19(5):1444-54
references: 11230490
references: Nature. 2006 May 4;441(7089):111-4
references: 16565705
references: Expert Opin Drug Deliv. 2008 Jan;5(1):25-44
references: 18095927
references: Acc Chem Res. 2011 Oct 18;44(10):979-89
references: 21902173
references: Nat Rev Clin Oncol. 2010 Sep;7(9):485-6
references: 20798696
references: Nat Biotechnol. 2010 Feb;28(2):172-6
references: 20081866
references: Cancer Cell. 2013 Jan 14;23(1):63-76
references: 23328481
references: Biochem Biophys Res Commun. 2011 Aug 12;411(4):804-8
references: 21787752
references: Nature. 1998 Feb 19;391(6669):806-11
references: 9486653
references: Nature. 2010 Apr 15;464(7291):1067-70
references: 20305636
references: Adv Enzyme Regul. 2001;41:189-207
references: 11384745
references: Mol Oncol. 2012 Jun;6(3):284-98
references: 22217540
references: Nat Biotechnol. 2009 Jul;27(7):643-51
references: 19561595
references: Curr Opin Genet Dev. 2005 Feb;15(1):102-11
references: 15661540
references: Ann Oncol. 2004 Mar;15(3):440-9
references: 14998846
references: Nat Cell Biol. 2008 May;10(5):593-601
references: 18376396
references: Cancer Res. 2009 Mar 15;69(6):2195-200
references: 19276373
references: Cancer Res. 2005 Aug 1;65(15):6910-8
references: 16061675
references: Science. 2007 Nov 16;318(5853):1108-13
references: 17932254
references: Cell. 2010 Jun 25;141(7):1195-207
references: 20603000
references: Curr Opin Chem Biol. 2011 Aug;15(4):463-8
references: 21704549